JPRN-UMIN000030612CompletedPhase 2
A multi-center clinical trial of tolerance induction using autologous regulatory T cells in liver transplantation - Treg multicenter clinical trial
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Hokkaido University Hospital
- Enrollment
- 1
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Recipient 1. A person who has no recognition capacity 2. A person who is judged inadequate for the protocol due to the following past history or ongoing infections 1) Bacterial infection such as Treponema pallidum, Neisseria gonorrhea or Mycobacterium tuberculosis 2) Sepsis 3) Malignant diseases (except for hepatocellular carcinoma) 4) Severe metabolic diseases 5) Collagen disease or hematological disorders 6) Transmissible spongiform encephalopathy or dementia 7) A specific hereditary disease or associated familial history 8) Human immunodeficiency virus infection 9) Human T-cell leukemia virus type 1 infection 10) Human parvovirus B19 infection 11) Active infection such as Cytomegalovirus, Epstein-Barr virus or West e virus 3. A person 1) with systolic blood pressure under 90 mmHg or over 180 mmHg, 2) with diastolic blood pressure under 50 mmHg or over 100 mmHg 4. A person considered ineligible due to some medical reasons by principal investigator or co-researchers Donor 1. A donor who has no recognition capacity 2. A donor who is judged inadequate for the protocol due to the following past history or ongoing infections 1) Bacterial infection such as Treponema pallidum, Neisseria gonorrhea or Mycobacterium tuberculosis 2) Sepsis 3) Malignant diseases 4) Severe metabolic diseases 5) Collagen disease or hematological disorders 6) Liver diseases 7) Transmissible spongiform encephalopathy or dementia 8) A specific hereditary disease or associated familial history 9) HBV infection 10) HCV infection 11) Human immunodeficiency virus infection 9) Human T-cell leukemia virus type 1 infection 10) Human parvovirus B19 infection 11) Active infection such as Cytomegalovirus, Epstein-Barr virus or West e virus 3. A donor 1) with systolic blood pressure under 90 mmHg or over 180 mmHg, 2) with diastolic blood pressure under 50 mmHg or over 100 mmHg 4. A person considered ineligible due to some medical reasons by principal investigator or co-researchers
Investigators
Similar Trials
Active, not recruiting
Phase 1
A multicenter study of the efficacy, tolerability, safety, and pharmacokinetics of Immune Globuline Subcutaneous (Human) IgPro20 in subjects with Primary Immunodeficiency (PID)PID (Primary Immunodeficiency)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2006-006745-13-PLCSL Behring51
Active, not recruiting
Not Applicable
Study to assess the tolerability and efficacy of AMG 145 in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.HypercholesterolaemiaMedDRA version: 14.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001529-26-FIAmgen Inc150
Active, not recruiting
Not Applicable
Study to assess the tolerability and efficacy of AMG 145 in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.HypercholesterolaemiaMedDRA version: 13.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001529-26-SEAmgen Inc150
Active, not recruiting
Phase 1
Study to assess the tolerability and efficacy of AMG 145 in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.EUCTR2011-001529-26-DKAmgen Inc150
Active, not recruiting
Phase 1
Study to assess the tolerability and efficacy of AMG 145 in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.HypercholesterolaemiaMedDRA version: 14.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001529-26-BEAmgen Inc150